Glenmark Pharmaceuticals Limited
GLENMARK
Peringkat dalam Saham
#2739
Glenmark Pharmaceuticals Limited, including its associated entities, is a... Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, Latin America, Europe, and other international regions. The company's diverse offerings comprise both branded and generic drug formulations, with a strategic emphasis on therapeutic areas such as dermatology, respiratory conditions, and oncology. Additionally, Glenmark manufactures and supplies a variety of active pharmaceutical ingredients. The company's robust product pipeline includes several investigational therapies. Among its clinical-stage assets are ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody currently in Phase 2b trials for atopic dermatitis; ISB 1302, a HER2 x CD3 bispecific antibody undergoing Phase 1/2 studies for metastatic HER2-positive breast cancer; and ISB 1342, a CD38 x CD3 bispecific antibody in Phase 1 development for relapsed/refractory multiple myeloma. In its preclinical pipeline, Glenmark is advancing ISB 880 for anti-inflammatory applications; the T-cell engagers ISB 1908 and ISB 1909 for oncology indications; ISB 1442, an innate immune engager also targeting oncology; and GRC 39815, a retinoid-related orphan receptor gamma inhibitor aimed at treating chronic obstructive pulmonary disorder (COPD). Among its commercially available products is Ryaltris nasal spray, prescribed for allergic rhinitis. Founded in 1977, Glenmark Pharmaceuticals Limited is headquartered in Mumbai, India.
Harga Saham
$24.39
Terakhir disinkronkan: 2026-10-19
Kapitalisasi Pasar
$6.88B
Perubahan (1 hari)
-1.20%
Perubahan (1 tahun)
15.69%
Negara
IN
Perdagangan Glenmark Pharmaceuticals Limited (GLENMARK)
Kategori
Healthcare
Laba untuk Glenmark Pharmaceuticals Limited (GLENMARK)
Laba pada Jun 2026 TTM: $279.49M
Menurut laporan keuangan terbaru dari Glenmark Pharmaceuticals Limited, laba saat ini perusahaan adalah $279.49M. Pada tahun 2024, perusahaan memperoleh laba sebesar $4.38M, penurunan dibandingkan dengan laba tahun 2023 sebesar $29.18M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Glenmark Pharmaceuticals Limited dari 2004 hingga 2026
Laba pada akhir setiap tahun
| Tahun | Laba | Mengubah |
|---|---|---|
| 2026 (TTM) | $279.49M | 70.84% |
| 2025 | $163.60M | 3,637.91% |
| 2024 | $4.38M | -85.00% |
| 2023 | $29.18M | -84.63% |
| 2022 | $189.86M | 0.54% |
| 2021 | $188.85M | 29.80% |
| 2020 | $145.49M | -22.32% |
| 2019 | $187.30M | 8.95% |
| 2018 | $171.91M | -11.53% |
| 2017 | $194.32M | 28.13% |
| 2016 | $151.66M | 59.24% |
| 2015 | $95.24M | -18.08% |
| 2014 | $116.26M | -14.52% |
| 2013 | $136.01M | 41.30% |
| 2012 | $96.26M | -10.92% |
| 2011 | $108.05M | 26.41% |
| 2010 | $85.48M | 61.39% |
| 2009 | $52.96M | -70.21% |
| 2008 | $177.80M | 113.31% |
| 2007 | $83.35M | 231.25% |
| 2006 | $25.16M | -13.68% |
| 2005 | $29.15M | 146.09% |
| 2004 | $11.85M | 0.00% |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan | Laba | Perbedaan Laba | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 531.35% |
IN
|
